130 related articles for article (PubMed ID: 38320051)
21. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT.
Constable L; Abrams P; Cooper D; Kilonzo M; Cotterill N; Harding C; Drake MJ; Pardoe MN; McDonald A; Smith R; Norrie J; McCormack K; Ramsay C; Uren A; Mundy T; Glazener C; MacLennan G
Health Technol Assess; 2022 Aug; 26(36):1-152. PubMed ID: 35972773
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
De B; Pasalic D; Barocas DA; Wallis CJD; Huang LC; Zhao Z; Koyama T; Tang C; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
J Urol; 2022 Dec; 208(6):1226-1239. PubMed ID: 36006050
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
[TBL] [Abstract][Full Text] [Related]
24. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
25. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
26. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
27. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
28. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
29. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; San-Segundo CG; Rodríguez MÁC; Solé JM; Olivé AP; Casas F; Boladeras A; de Vidales CM; de la Torre MLV; Vara S; Sanz JL; Calvo FA
Lancet Oncol; 2022 May; 23(5):671-681. PubMed ID: 35427469
[TBL] [Abstract][Full Text] [Related]
30. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy.
Shrader-Bogen CL; Kjellberg JL; McPherson CP; Murray CL
Cancer; 1997 May; 79(10):1977-86. PubMed ID: 9149026
[TBL] [Abstract][Full Text] [Related]
31. Population-based study of long-term functional outcomes after prostate cancer treatment.
Carlsson S; Drevin L; Loeb S; Widmark A; Lissbrant IF; Robinson D; Johansson E; Stattin P; Fransson P
BJU Int; 2016 Jun; 117(6B):E36-45. PubMed ID: 25959859
[TBL] [Abstract][Full Text] [Related]
32. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
33. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
34. Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study.
Vernooij RWM; Cremers RGHM; Jansen H; Somford DM; Kiemeney LA; van Andel G; Wijsman BP; Busstra MB; van Moorselaar RJA; Wijnen EM; Pos FJ; Hulshof MCCM; Hamberg P; van den Berkmortel F; Hulsbergen-van de Kaa CA; van Leenders GJLH; Fütterer JJ; van Oort IM; Aben KKH
Urol Oncol; 2020 Sep; 38(9):735.e17-735.e25. PubMed ID: 32680820
[TBL] [Abstract][Full Text] [Related]
35. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
Tyson MD; Koyama T; Lee D; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen V; Conwill R; McCollum D; Penson DF; Barocas DA
Eur Urol; 2018 Jul; 74(1):26-33. PubMed ID: 29501451
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
37. Prediction of erectile function following treatment for prostate cancer.
Alemozaffar M; Regan MM; Cooperberg MR; Wei JT; Michalski JM; Sandler HM; Hembroff L; Sadetsky N; Saigal CS; Litwin MS; Klein E; Kibel AS; Hamstra DA; Pisters LL; Kuban DA; Kaplan ID; Wood DP; Ciezki J; Dunn RL; Carroll PR; Sanda MG
JAMA; 2011 Sep; 306(11):1205-14. PubMed ID: 21934053
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
39. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy.
Fulmer BR; Bissonette EA; Petroni GR; Theodorescu D
Cancer; 2001 Jun; 91(11):2046-55. PubMed ID: 11391584
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.
Madalinska JB; Essink-Bot ML; de Koning HJ; Kirkels WJ; van der Maas PJ; Schröder FH
J Clin Oncol; 2001 Mar; 19(6):1619-28. PubMed ID: 11250990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
